Menu
1 min read · estimated
APPROVED USE
What FDA approved
For adults and children age 2 years or older with hematopoietic stem cell transplant-associated thrombotic microangiopathy.
LAMPGEN ANALYSIS
Why it matters
This MASP-2 inhibitor is the first approved treatment for the potentially life-threatening post-transplant complication.
What research teams should watch
Plan rapid transplant-team recognition of TA-TMA and track blood markers, transfusion needs, organ function, and infections.
PRIMARY RECORDS